GLP-1 Analogues Market to Reach US$299.08 Billion by 2033 as Obesity, Type 2 Diabetes and Cardiometabolic Care Reshape Global Treatment Demand

NEW YORK, May 24, 2026 - According to DataM Intelligence, the global Glucagon-like Peptide 1, or GLP-1, Analogues Market reached US$62.81 billion in 2024 and is expected to reach US$299.08 billion by 2033, growing at a CAGR of 17.6% during 2026 to 2033. The market is segmented by product into Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and others, by type into long-acting GLP-1 agonists and short-acting GLP-1 agonists, by route of administration into subcutaneous and oral, and by application into type 2 diabetes mellitus, obesity and others.

The global GLP-1 analogues market is entering an exceptional growth cycle as obesity, type 2 diabetes and broader cardiometabolic disorders converge into one of the most attractive treatment opportunities in global pharmaceuticals. On a growth-multiple basis, the market is expected to expand nearly 4.76x by 2033, reflecting the rapid transition of GLP-1 therapies from diabetes-focused drugs into multi-indication metabolic care platforms.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/glucagon-like-peptide-1-analogues-market?kailas

Why GLP-1 Analogues Are a Highly Sellable Pharmaceutical Market

GLP-1 analogues are highly sellable because they sit at the intersection of three powerful demand drivers: rising type 2 diabetes prevalence, global obesity growth and expanding evidence for cardiometabolic risk reduction. These therapies replicate the activity of the naturally occurring GLP-1 hormone, supporting glucose regulation by enhancing insulin secretion, inhibiting glucagon release and promoting satiety. DataM Intelligence notes that GLP-1 analogues are mainly used to treat type 2 diabetes and obesity because they help lower blood sugar levels and support weight loss by reducing appetite and caloric intake.

The sellability of this market is strengthened by its broad product ecosystem. Unlike narrow therapeutic categories dependent on one molecule or one indication, the GLP-1 landscape includes established blockbuster brands, next-generation dual agonists, oral formulations, biosimilars, generics and pipeline candidates. Products such as Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Saxenda, Victoza and Trulicity create a market with multiple commercial entry points across diabetes care, obesity treatment and emerging metabolic disease indications.

Obesity and Type 2 Diabetes Create a Massive Demand Foundation

The core growth driver is the rising prevalence of obesity and type 2 diabetes. WHO data show that in 2022, 43% of adults aged 18 years and older were overweight and 16% were living with obesity, while 890 million adults were living with obesity globally. WHO also reported that more than 390 million children and adolescents aged 5 to 19 were overweight in 2022, including 160 million living with obesity.

Diabetes adds another major demand layer. WHO reported that the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022, with prevalence rising faster in low- and middle-income countries than in high-income countries. More than half of people living with diabetes did not take medication for diabetes in 2022, pointing to a major treatment-access gap and long-term opportunity for better disease management.

GLP-1 Drugs Are Moving Beyond Glucose Control into Cardiometabolic Care

The GLP-1 market is becoming more commercially powerful because the therapy class is expanding beyond blood sugar control. These drugs are increasingly positioned around weight management, cardiovascular risk reduction, kidney disease risk reduction and broader metabolic health. In March 2024, the U.S. FDA approved Wegovy, or semaglutide injection, to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight, in addition to a reduced-calorie diet and increased physical activity.

This expansion is critical because it changes GLP-1 analogues from chronic diabetes medicines into broader cardiometabolic therapies. As labels expand and outcomes data strengthen, GLP-1 drugs can reach more patients, more prescribers and more reimbursement pathways. DataM Intelligence also notes that in January 2025, FDA approved Ozempic as the first GLP-1 receptor agonist specifically indicated to reduce the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW phase 3b clinical trial.

Ozempic Holds a Leading Product Position

Ozempic is expected to hold 27.5% of the global GLP-1 market in 2024, according to DataM Intelligence. The report explains that Ozempic selectively binds to and activates the GLP-1 receptor, mimicking native GLP-1 activity while structural modifications extend its half-life and enable once-weekly dosing. This dosing convenience has become a major competitive advantage in chronic disease management, where adherence, patient experience and long-term use are central to treatment success.

Ozempic's leadership also reflects the strength of semaglutide-based products across the GLP-1 class. Semaglutide has become one of the most recognized molecules in metabolic care, supported by diabetes control, weight-management demand and expanded outcomes data. As GLP-1 products move into broader cardiometabolic settings, established brands with strong clinical familiarity and physician adoption are likely to remain central to market growth.

Oral GLP-1 and Next-Generation Molecules Open a New Growth Frontier

The market is entering a new innovation phase led by oral GLP-1 agonists, longer-acting formulations and combination therapies. DataM Intelligence identifies the introduction of innovative products such as CagriSema and oral GLP-1 agonists as key trends reshaping the market. Oral delivery is especially important because it can reduce dependence on injections, improve patient convenience and potentially expand adoption among patients who are reluctant to use injectable therapies.

Pipeline activity is also intensifying. In January 2025, Metsera reported positive topline Phase IIa results for MET-097i, an investigational GLP-1 receptor agonist designed for obesity with potential once-monthly dosing. In September 2024, Terns Pharmaceuticals announced positive Phase 1 results for TERN-601, a once-daily oral GLP-1 receptor agonist for obesity. These developments show how the market is moving toward improved dosing frequency, stronger convenience and broader patient reach.

Obesity Drug Demand Creates a New Revenue Engine

The rapid growth of the obesity drug segment is one of the defining trends in the GLP-1 analogues market. DataM Intelligence highlights the increasing acceptance of GLP-1 therapies for chronic weight management as a major source of new revenue. The report also cites Eli Lilly's August 2024 positive topline results from the SURMOUNT-1 trial, evaluating tirzepatide for long-term weight management and delaying progression to diabetes in adults with pre-diabetes and obesity or overweight.

This matters because obesity treatment is shifting from lifestyle-only management toward long-term pharmacological care. As obesity is increasingly recognized as a chronic disease associated with type 2 diabetes, cardiovascular disease, hypertension, metabolic syndrome, bone health issues, reproductive health effects and certain cancers, demand for effective medical intervention is likely to strengthen. WHO notes that obesity is associated with serious health risks and can affect quality of life, mobility and sleep.

North America and Europe Control More Than 70% of Market Share

North America and Europe together account for more than 70% of the global GLP-1 analogues market, according to DataM Intelligence. North America alone is expected to hold 42.5% of the global market in 2024, supported by rising obesity and type 2 diabetes prevalence, advanced healthcare infrastructure, favourable reimbursement frameworks and high adoption of advanced therapies.

The region is also benefiting from expanded product availability. In December 2024, FDA approved the first generic version of Victoza, or liraglutide injection, for adults and children aged 10 years and older with type 2 diabetes as an add-on to diet and exercise to improve glycemic control. This generic approval strengthens the access story and could support wider uptake across patient groups where affordability has been a barrier.

Asia Pacific Becomes a High-Growth Access and Volume Market

Asia Pacific is expected to hold 19.8% of the global GLP-1 analogues market in 2024, supported by increasing type 2 diabetes and obesity rates, urbanization, lifestyle changes and an aging population. DataM Intelligence notes that individuals aged 60 and above in Asia Pacific are projected to nearly double by 2050, increasing the population vulnerable to type 2 diabetes and related metabolic disorders.

The region is also seeing biosimilar and affordability-driven activity. In January 2024, Glenmark Pharmaceuticals launched Lirafit, a biosimilar of liraglutide, in India after approval from the Drug Controller General of India. This marked the first introduction of a liraglutide biosimilar in India and highlights how emerging markets may expand access through biosimilars, generics and localized commercialization strategies.

Cost Remains a Major Barrier, but Also Confirms Premium Market Value

High cost is the most significant restraint in the GLP-1 analogues market. DataM Intelligence notes that monthly treatment expenses can reach about US$1,000, making access difficult for many patients without comprehensive insurance coverage. The report cites Yale School of Medicine data indicating that semaglutide products such as Ozempic and Wegovy may cost Americans up to approximately US$1,000 per month, while estimated cost-based prices for GLP-1 agonists could be far lower.

This cost barrier creates two opposing market forces. On one hand, affordability and reimbursement constraints may limit access. On the other hand, premium pricing confirms the market's high commercial value and intensifies competition around generics, biosimilars, oral alternatives and next-generation molecules. Companies that can improve access while preserving clinical differentiation are likely to gain significant market advantage.

Competitive Landscape: Blockbuster Brands and Emerging Biotech Players Reshape the Market

The global GLP-1 analogues market includes major companies such as Eli Lilly and Company, Novo Nordisk A/S, Sanofi, AstraZeneca, Boehringer Ingelheim, Glenmark Pharmaceuticals, Hanmi Pharm, Amgen, Gmax Biopharm and Sciwind Biosciences. Emerging players include Teva Pharmaceuticals, Hikma, Viking Therapeutics, Terns Pharmaceuticals, Altimmune, AVVA Pharmaceuticals, Lexicare Pharma and Natco Pharma, among others.

Recent developments show accelerating competition. In April 2025, Meitheal Pharmaceuticals received FDA approval for liraglutide injection and launched the product in the U.S. market. In February 2025, Biocon launched liraglutide in the United Kingdom. In June 2024, Teva launched the first generic version of a GLP-1 receptor agonist in the U.S., specifically liraglutide 1.8 mg. These developments indicate that the market is entering a new phase where blockbuster demand, generic access and pipeline innovation will evolve together.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=glucagon-like-peptide-1-analogues-market?kailas

Strategic Outlook: GLP-1 Analogues Become a Defining Market in Metabolic Medicine

The GLP-1 analogues market is positioned for sustained high growth because it addresses some of the most common and costly chronic conditions worldwide. Rising obesity prevalence, growing diabetes burden, expanding cardiovascular and kidney-related indications, oral GLP-1 development, longer-acting molecules and biosimilar competition are all reshaping the market's commercial future.

With the market projected to rise from US$62.81 billion in 2024 to US$299.08 billion by 2033, GLP-1 analogues are becoming one of the most important pharmaceutical categories of the decade. The next phase of competition will be shaped by efficacy, safety, dosing convenience, access, reimbursement, oral delivery, combination therapy and label expansion across cardiometabolic disease. For market positioning, the report is highly sellable because it covers a therapy class with blockbuster revenue, major public health relevance, strong clinical momentum and continuous commercial disruption.

About the Report

The Glucagon-like Peptide 1, or GLP-1, Analogues Market report by DataM Intelligence analyzes the market by product, type, route of administration, application, distribution channel and region. Product coverage includes Ozempic, Trulicity, Mounjaro, Wegovy, Rybelsus, Saxenda, Victoza, Zepbound and others. Application coverage includes type 2 diabetes mellitus, obesity and other indications, while distribution channels include hospital pharmacies, retail pharmacies and online pharmacies across North America, Latin America, Europe, Asia Pacific, the Middle East and Africa.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.